ABSTRACT
Third doses of COVID-19 vaccines were widely deployed following primary vaccine course waning and emergence of the Omicron-variant. We investigated protection from third-dose vaccines and previous infection against SARS-CoV-2 infection during Delta-variant and Omicron-variant (BA.1 & BA.2) waves in our frequently PCR-tested cohort of healthcare-workers.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://doi.org/10.1136/bmjopen-2021-054336
Funding Statement
The SIREN study is funded by UK Health Security Agency and the Department of Health, with contributions from the Northern Irish, Scottish and Welsh governments. The study receives support from the National Institute for Health Research (NIHR) as an Urgent Priority Study. SH and VJH are supported by the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with UKHSA (NIHR200915). FI was supported by Imperial College's President's PhD Scholarship. The study has received grant funding from the Medical Research Council (Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway, MR/W02067X/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Berkshire Research Ethics Committee of NHS Health Research Authority gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The metadata will be available through the Health Data Research UK Co-Connect platform. Anonymised data will be made available for secondary analysis to trusted researchers upon reasonable request.
